Autres langues NFL Biosciences

Actions

ALNFL

FR0014003XT0

Recherche biotechnologique et médicale

PEA

PEA/PME

Temps réel Euronext Paris 11:46:05 17/08/2026			Varia. 5j.	Varia. 1 janv.
0,8500 ^EUR	+2,16 %		-1,85 %	-27,84 %

28/07	NFL Biosciences dépose une demande d'autorisation pour l'essai clinique de Phase 2 TONIC évaluant le NFL-102 dans le sevrage tabagique	CI
07/07	NFL Biosciences présente trois communications scientifiques sur NFL-101 et NFL-102 lors de la conférence SRNT-Europe 2026	CI

Autres langues

28/07	NFL Biosciences Submits an Application for Authorization of the Phase 2 TONIC Clinical Trial Evaluating NFL-102 in Smoking Cessation
28/07	NFL Biosciences Submits Application For Authorization Of The Phase 2 Tonic Clinical Trial Evaluating NFL-102 In Smoking Cessation
07/07	Nfl Biosciences Presents Three Scientific Communications on Nfl-101 and Nfl-102 At 2026 Srnt-Europe Conference
07/07	International Scientific Recognition for NFL Biosciences: 3 Presentations Selected at the 2026 SRNT-Europe Conference, Including an Oral Presentation on NFL-102
30/06	NFL Biosciences Successfully Manufactures GMP Clinical Batch Of NFL-102 And Validates Industrial Production Chain
30/06	NFL Biosciences Announces the Successful Manufacturing of a GMP Clinical Batch of NFL-102 and Validates Its Industrial Production Chain
01/06	NFL Biosciences Releases New Results on NFL-101 and Reaffirms Its Personalized Approach to Smoking Cessation
01/06	NFL Biosciences Releases New Results on NFL-101 and Reaffirms Its Personalized Approach to Smoking Cessation
26/05	NFL Biosciences to File Patent Application for Smoking Cessation Drug-linked Biomarker
25/05	NFL Biosciences Is Strengthening Its Personalized Medicine Approach to Smoking Cessation With a New Patent Application
25/05	NFL Biosciences Files Patent Application Protecting Predictive Efficacy Biomarker Associated With NFL-101
11/05	NFL Biosciences SA Clarifies Objectives And Evaluation Criteria For Predictive Biomarker Associated With NFL-101
11/05	NFL Biosciences Clarifies the Objectives and Evaluation Criteria for a Predictive Biomarker Associated With NFL-101
04/05	NFL Biosciences: International Scientific Community’s Interest in NFL-102 for Smoking Cessation Confirmed by the Selection of Its Work at Two Leading Conferences
04/05	NFL Biosciences Presents Work On NFL-102 For Smoking Cessation At International Scientific Conferences
15/04	NFL Biosciences SA Reports Earnings Results for the Full Year Ended December 31, 2025
15/04	NFL Biosciences Presents Its 2025 Annual Results and Provides an Update on Its Clinical Progress Driven by a New Paradigm in Smoking Cessation
15/04	NFL Biosciences Strengthens Its Cash Position by €2.6 Million Through Bond Financing Subscribed by a Group of European Institutional Investors
15/04	NFL Biosciences SA announced that it expects to receive ?2.6 million in funding from Vester Finance
13/04	Weekly Earnings Calendar: JPMorgan and Netflix in the US, LVMH and ASML in Europe,
07/04	A New Paradigm in Tobacco and Nicotine Addiction: NFL Biosciences Demonstrates the Mechanism of Action of NFL-102 in a Video
11/03	NFL BIOSCIENCES Secures EUR 500,000 Loan from Bpifrance
11/03	NFL Biosciences : Inside Information / Other news releases
11/03	Bpifrance Renews Its Confidence in NFL Biosciences Through the Granting of a €500,000 Loan
19/02	NFL Biosciences Publishes Its 2026 Financial Agenda